L

Liquidia Corp
D

LQDA

11.230
USD
0.59
(5.55%)
Market Closed
Volume
0
EPS
-2
Div Yield
-
P/E
-7
Market Cap
950,469,254
OverviewSignalsIdeasNews
Related Instruments
    A
    ABEO
    -0.09500
    (-1.60%)
    5.85500 USD
    B
    BLUE
    -0.04270
    (-11.74%)
    0.32090 USD
    C
    CRSP
    0.360
    (0.77%)
    47.280 USD
    E
    EDIT
    -0.11500
    (-4.14%)
    2.66500 USD
    GILD
    GILD
    -3.715
    (-4.03%)
    88.385 USD
    N
    NTLA
    -1.165
    (-7.71%)
    13.955 USD
    PFE
    PFE
    -1.225
    (-4.71%)
    24.800 USD
    REGN
    REGN
    -25.40
    (-3.25%)
    756.82 USD
    S
    SGMO
    -0.10000
    (-4.67%)
    2.04000 USD
    SNY
    SNY
    0.160
    (0.33%)
    47.980 USD
    More
News

Title: Liquidia Corp

Sector: Healthcare
Industry: Biotechnology
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.